Bedrijfsoverzicht
ARS Pharmaceuticals, Inc. is a biopharmaceutical entity focused on the research, development, and commercialization of therapeutic solutions for severe allergic reactions within the United States and global markets. The company operates within the broader Healthcare sector, specifically functioning in the specialized sub-industry of Biotechnology, which implies a reliance on scientific innovation and regulatory approval processes for product launch. As of the latest data, the organization employs 158 individuals and holds a total market capitalization of $799.34M, generating annual revenue of $84.28M over the trailing twelve months. These financial metrics indicate that the company maintains a significant market presence relative to its operational scale, positioning it as a mid-cap player with a substantial asset base to fund its pipeline, despite the inherent volatility associated with early-stage biotechnology development.
Financiële gezondheid
The company reported a revenue of $84.28M for the trailing twelve months, yet this income was offset by a net income of $-171,298,000 and an EBITDA of $-178,080,992. The substantial negative gap between the $84.28M in revenue and the $-171,298,000 in net income reveals a highly aggressive cost structure where operating expenses significantly exceed gross margins, likely driven by heavy investment in clinical trials and R&D typical of the biotechnology sector. Free cash flow stands at $-94,588,376, which indicates that the company is currently burning cash to fund its operations and development efforts, thereby limiting its immediate financial flexibility for external acquisitions or capital distributions. Margins reflect this financial pressure, with a gross margin of 60.1%, an operating margin of -147.6%, and a profit margin of -203.3%; the negative operating and profit margins demonstrate that overhead and R&D costs are consuming more than the gross profit generated from sales. Regarding liquidity, the company holds $244.99M in cash against $168.51M in debt, resulting in a debt-to-equity ratio of 147.49, which suggests a highly leveraged balance sheet where equity is minimal relative to total liabilities. Despite the high debt load, the current ratio is a robust 7.28, indicating that the company possesses ample current assets to cover its short-term obligations without immediate distress. Furthermore, the return on equity is -92.3% and the return on assets is -33.0%, metrics that reveal that management effectiveness is currently measured by cost containment and pipeline advancement rather than generating immediate shareholder returns.
Waarderingsbeoordeling
Valuation metrics for ARS Pharmaceuticals are heavily influenced by its lack of profitability, evidenced by a P/E ratio (TTM) of N/A and a forward P/E of -11.14. The negative forward P/E implies that the market is pricing in a trajectory of continued losses or that earnings are expected to remain negative in the near term, making traditional earnings-based valuation methods inapplicable. Investors must instead rely on the price-to-book ratio of 6.99, which indicates that the stock is trading at a significant premium to its book value, suggesting that the market assigns high potential value to the company's intangible assets and drug pipeline. Alternative valuation measures such as the price-to-sales ratio of 9.48 and an EV/EBITDA of -4.06 further highlight that the company is valued on revenue generation potential rather than current earnings power. Price action shows a 52-week high of $18.90 and a 52-week low of $6.66, meaning the stock currently trades within a range that reflects significant market sentiment shifts over the past year. The beta of 0.93 suggests that the stock's price volatility is roughly in line with the broader market, moving with similar intensity to the overall market index during periods of fluctuation.
Growth & Income
The company's financial trajectory shows a revenue growth year-over-year of -67.6%, while earnings growth is N/A due to the lack of positive earnings in the period. This contraction in revenue indicates a challenging sales environment or a reduction in the commercial footprint of its products, whereas the absence of earnings growth metrics simply reflects the persistent unprofitability rather than a specific divergence in growth rates between top-line and bottom-line figures. As the company does not distribute dividends, there is a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash flow is retained within the organization to fund ongoing research, development, and operational expenses rather than being paid out to shareholders. Consequently, the overall growth and income profile for ARS Pharmaceuticals is characterized by a current period of contraction and zero dividend income, requiring reliance on retained earnings and external financing to sustain future development activities.